Business UpdateAug 13, 2026, 06:01 AM
Bluejay Diagnostics Completes SYMON-II Enrollment, $9.6M Cash
AI Summary
Bluejay Diagnostics announced the completion of targeted patient enrollment for its SYMON-II pivotal clinical study, a key step towards FDA 510(k) submission for its Symphony IL-6 test. The company also reported a strong financial position, ending the second quarter of 2026 with approximately $9.6 million in cash and cash equivalents, following significant financing activities. This financial strength is expected to fund operations through the second quarter of 2027, supporting regulatory and commercialization efforts.
Key Highlights
- Completed targeted enrollment of 750 patients in the SYMON-II pivotal clinical study.
- Ended Q2 2026 with approximately $9.6 million in cash and cash equivalents.
- Generated approximately $7.7 million net cash from financing activities in H1 2026.
- Received approximately $7.6 million net proceeds from June 2026 private placement.
- Cash resources estimated to fund operations through Q2 2027.
Price Impact
More from BJDX